Cadence Pharmaceuticals Announces Favorable Court Ruling In OFIRMEV Patent Litigation

Cadence Pharmaceuticals (NASDAQ: CADX ) announced today that the U.S. District Court for the District of Delaware has ruled in favor of Cadence in the company's patent infringement lawsuit against Exela Pharma Sciences, LLC. "We are very pleased with the Court's decision, as it confirms our belief in the